The US Food and Drug Administration has approved Hibsago (bepirovirsen), the first treatment that offers a functional cure for chronic hepatitis B, a disease affecting more than 250 million people worldwide and causing upwards of a million deaths each year. Clinical trials showed that 19% of patients achieved undetectable virus levels 24 weeks after stopping all therapy, compared with less than 1% under standard care.
organisation
US Food and Drug Administration
US federal agency responsible for regulating food, drugs and medical products